VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).

Mineur, P; Ménard, J F; Le Loët, X; Bernard, J F; Grosbois, B; Pollet, J P; Azais, I; Laporte, J P; Doyen, C; De Gramont, A; Wetterwald, M; Euller-Ziegler, L; Peny, A M; Monconduit, M; Michaux, J L

Mineur, P; Ménard, J F; Le Loët, X; Bernard, J F; Grosbois, B; Pollet, J P; Azais, I; Laporte, J P; Doyen, C; De Gramont, A; Wetterwald, M; Euller-Ziegler, L; Peny, A M; Monconduit, M; Michaux, J L.

Affiliation

Mineur P; Médecine Interne, Hôpital St Joseph, Gilly, Belgium.

Br J Haematol ; 103(2): 512-7, 1998 Nov.

Article in En | MEDLINE | ID: mdl-9827927

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Multiple Myeloma/drug therapy; Adult; Aged; Aged, 80 and over; Carmustine/administration & dosage; Cyclophosphamide/administration & dosage; Dexamethasone/administration & dosage; Doxorubicin/administration & dosage; Female; Humans; Male; Melphalan/administration & dosage; Middle Aged; Prednisone/administration & dosage; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 1998 Document type: Article

Search on Google

XML

PubMed Links